Adalimumab for rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 6, Issue 12, 2006, Pages 1349-1360

  Voulgari, Paraskevi V ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adalimumab; Efficacy; Rheumatoid arthritis; Safety; TNF inhibitors

Indexed keywords

ADALIMUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

AGRANULOCYTOSIS; ALLERGIC REACTION; B CELL LYMPHOMA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; BRONCHITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE COURSE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GUILLAIN BARRE SYNDROME; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; MAXIMUM ALLOWABLE CONCENTRATION; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE SCLEROSIS; NONHUMAN; PANCYTOPENIA; PATHOGENESIS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845349216     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.12.1349     Document Type: Review

References (64)

1. LINDQVIST E, JONSSON K, SAXNE T, EBERHARDT K: Course of radiographic damage of 10 years in a cohort with early rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:611-616.
2. WELSING PM, VAN GESTEL AM, SWINKELS HL, KIEMENEY LA, VAN RIEL PL: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. (2001) 44:2009-2017.
3. DROSOS AA, ALAMANOS I, VOULGARI PV et al.: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J. Rheumatol. (1997) 24:2129-2133.
4. UHLIG T, KVIEN TK, GLENNAS A, SMEDSTAD LM, FORRE O: The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J. Rheumatol. (1998) 25:1078-1084.
5. UHLIG T, KVIEN TK: Is rheumatoid arthritis disappearing? Ann. Rheum. Dis. (2005) 64:7-10.
6. ALAMANOS Y, DROSOS AA: Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. (2005) 4:130-136.
7. BRENNAN FM, MAINI RN, FELDMANN M: TNFα - a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. (1992) 31:293-298.
8. FIRESTEIN GS: The immunopathogenesis of rheumatoid arthritis. Curr. Opin. Rheumatol. (1991) 3:398-406.
9. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
10. DROSOS AA: Newer immunosuppressive drugs: their potential role in rheumatoid arthritis. Drugs (2002) 62:891-907. • Description of the pathophysiology of RA and the role of immunosuppressive drugs in RA.
11. DROSOS AA: Methotrexate intolerance in elderly rheumatoid arthritis patients: what are the alternatives? Drug Aging (2003) 20:723-736.
12. KIRWAN JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. (1995) 333:142-146.
13. SVENSSON B, BOONEN A, ALBERTSSON K, VAN DER HEIJDE D, KELLER C, HAFSTROM I: Low-dose prednisone in addition to the initial disease-modifying antirheumatic drug in patients with early rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. (2005) 52:3360-3370.
14. PAPADOPOULOS NG, ALAMANOS Y, PAPADOPOULOS IA, TSIFETAKI N, VOULGARI PV, DROSOS AA: Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J. Rheumatol. (2002) 29:261-266.
15. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 353:259-266.
16. DROSOS AA, VOULGARI PV, KATSARAKI A, ZIKOU AK: Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol. Int. (2000) 19:113-118.
17. WEINBLATT ME, REDA D, HENDERSON W et al.: Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J. Rheumatol. (1999) 26:2123-2130.
18. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110. • The first full original paper of infliximab efficacy in RA.
19. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
20. BANG LM, KEATING GM: Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs (2004) 18:121-139. • Review article of adalimumab use in RA.
21. ABBOTT: Humira® [package insert]. Abbott, Abbott Park, IL, USA (2006).
22. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. (2005) 353:1114-1123.
23. EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targered therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2572-2581.
24. SANTORA LC, KRULL IS, GRANT K: Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal. Biochem. (1999) 275:98-108.
25. BARRERA P, JOOSTEN LA, DEN BROEDER AA, VAN DE PUTTE LB, VAN RIEL PL, VAN DEN BERG WB: Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2001) 60:660-669.
26. DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilabe turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311-318. • The first full original paper on the effect of adalimumab on radiological course in RA.
27. AWNI WM, CASCELLA P, OLEKA NA et al.: Steady-state pharmacokinetics (PK) of adalimumab (Humira™, Abbott) following 40 mg subcutaneous (SC) injection every other week (EOW) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy [abstract n 259]. Arthritis Rheum. (2003) 48(9 Suppl.):S140.
28. DEN BROEDER A, VAN DE PUTTE L, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:2288-2298.
29. RAU R, SANDER O, DEN BROEDER A et al.: Long term efficacy and tolerability of multiple iv doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41(Suppl.):S55.
30. SCHATTENKIRCHNER M, KRUGER K, SANDER O et al.: Efficacy and tolerability of weekly subcutaneous injections of the full human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41(Suppl.):S57.
31. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant stantdard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. (2003) 30:2563-2571.
32. VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. (2004) 63:508-516.
33. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45. • Description of combined efficacy of adalimumab and methotrexate.
34. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50:1400-1411. • Description of radiographic inhibition with adalimumab and methotrexate.
35. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. (2006) 54:26-37. • The first study of adalimumab in early RA.
36. WEINBLATT ME, KEYSTONE EC, FURST DE, KAVANAUGH AF, CHARTASH EK, SEGURADO OG: Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann. Rheum. Dis. (2006) 65:753-759.
37. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
38. VAN GESTEL AM, ANDERSON JJ, VAN RIEL PL et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology). Rheumatology (1999) 26:705-711.
39. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenry-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. (1995) 38:44-48.
40. WARE JE JR, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care (1992) 30:473-483.
41. FRIES JF, SPITZ PW, YOUNG DY: The dimentions of health outcomes: the health assessment questionnaire, disability and pain scales. J. Rheumatol. (1982) 9:789-793.
42. WEBSTER K, CELLA D, YOST K: The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual. Life Outcomes (2003) 1:79.
43. CELLA D, WEBSTER K: Linking outcomes management to quality-of-life measurement. Oncology (Williston Park) (1997) 11:232.
44. SHARP JT, LIDSKY MD, COLLINS LC, MORELAND J: Methods of scoring the progression of radiographic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. (1971) 14:706-720.
45. SHARP JT, YOUNG DY, BLUHM GB et al.: How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. (1985) 28:1326-1335.
46. BURMESTER GR, MONTEAGUDO SAEZ I, MAILAISE M, CANAS DA SILVA J, WEBBER D, KUPPER H: Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year results of ReAct study. Arthritis Rheum. (2005) 52(Suppl.):S541.
47. BOMBARDIERI S, TZIOUFAS AG, MCKENNA F, OZER U, HUPPER H: Adalimumab (Humira®) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life clinical setting. Arthritis Rheum. (2005) 52(Suppl.):S144.
48. WICK MC, ERNESTAM S, LINDBLAD S, BRATT J, KLARESKOG L, VAN VOLLENHOVEN RF: Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand. J. Rheumatol. (2005) 34:353-358.
49. GOMEZ-REINO JJ, CARMONA L: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. BIOBADASER GROUP. Arthritis Res. Ther. (2006) 8:R29.
50. NIKAS SN, VOULGARI PV, ALAMANOS Y et al.: The efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann. Rheum. Dis. (2006) 65:257-260.
51. ZIKOU AK, ARGYROPOULOU MI, VOULGARI PV et al.: Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J. Rheumatol. (2006) 33:219-223. • Description of the effects of adalimumab on radiological damage in RA using MRI.
52. ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (2006) 45:1294-1297.
53. GILES JT, BARTLETT SJ, GELBER AC et al.: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. (2006) 55:333-337.
54. CARMONA L, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. (2005) 52:1766-1772.
55. HYRICH KL, SYMMONS DP, WATSON KD, SILMAN AJ: Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. British Society, for Rheumatology Biologics Register. Arthritis Rheum. (2006) 54:2701-2702.
56. BEUTHIEN W, MELLINGHOFF HU, VON KEMPIS J: Skin reaction to adalimumab. Arthritis Rheum. (2004) 50:1690-1692.
57. NIKAS SN, VOULGARI PV, DROSOS AA: Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin. Rheumatol. (2006):1-2.
58. SCHIFF M, VAN DE PUTTE LB, LREEDVELD FC et al.: Rares of infection in adalimumab rheumatoid arthritis clinical trials [abstract THU0246]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):184.
59. SCHIFF MH, BURMESTER GR, KENT JM et al.: Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65:889-894.
60. DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. (2003) 48:1015-1023.
61. ERIKSSON C, ENGSTRAND S, SUNDQVIST KC, RANTAPAA-DAHLQVIST S: Antibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. (2005) 64:403-407.
62. ALESSANDRI C, BOMBARDIERI M, PAPA N et al.: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. (2004) 63:1218-1221.
63. ATZENI F, SARZI-PUTTINI P, DELL' ACQUA D et al.: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther. (2005) 8:R3.
64. http://www.emea.eu.int European Agency for Evaluation of Medicinal Products: Adalimumab: summary of product characteristics [online]. Accessed 13 June 2006.